UBS Group
MNPR icon

UBS Group’s Monopar Therapeutics MNPR Stock Holding History

UBS Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.16M Buy
39,436
+35,186
+828% +$2.13M ﹤0.01% 4901
2025
Q4 		$278K Sell
4,250
-3,723
-47% -$304K ﹤0.01% 6410
2025
Q3 		$651K Sell
7,973
-13,900
-64% -$621K ﹤0.01% 5901
2025
Q2 		$783K Buy
21,873
+13,752
+169% +$499K ﹤0.01% 5647
2025
Q1 		$296K Buy
8,121
+1,698
+26% +$61.2K ﹤0.01% 6258
2024
Q4 		$141K Buy
6,423
+5,911
+1,154% +$99.2K ﹤0.01% 6667
2024
Q3 		$3.45K Buy
+512
New +$1.71K ﹤0.01% 8264
2024
Q2 		– Sell
-514
Closed -$1.75K – 9888
2024
Q1 		$1.75K Sell
514
-1,866
-78% -$5.56K ﹤0.01% 8059
2023
Q4 		$4.05K Buy
2,380
+2,366
+16,900% +$4.79K ﹤0.01% 7909
2023
Q3 		$45 Buy
+14
New +$49 ﹤0.01% 9023
2023
Q2 		– Sell
-1,278
Closed -$8.88K – 9374
2023
Q1 		$8.88K Buy
1,278
+647
+103% +$9.58K ﹤0.01% 7688
2022
Q4 		$7.47K Sell
631
-449
-42% -$5.48K ﹤0.01% 8891
2022
Q3 		$8K Sell
1,080
-2,832
-72% -$26.8K ﹤0.01% 8730
2022
Q2 		$45K Buy
3,912
+3,291
+530% +$37.2K ﹤0.01% 6000
2022
Q1 		$8K Buy
621
+8
+1% +$118 ﹤0.01% 8681
2021
Q4 		$10K Buy
+613
New +$13.6K ﹤0.01% 8788
2021
Q2 		– Sell
-114
Closed -$4K – 9636
2021
Q1 		$4K Sell
114
-76
-40% -$2.77K ﹤0.01% 8420
2020
Q4 		$6K Buy
+190
New +$4.9K ﹤0.01% 7764
2020
Q2 		– Sell
-3
Closed – – 8195
2020
Q1 		$0 Sell
3
-255
-99% -$16K ﹤0.01% 8226
2019
Q4 		$21K Buy
+258
New +$26.9K ﹤0.01% 6848

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's MNPR Position: Q1 2026 in Review

UBS Group increased its Monopar Therapeutics (MNPR) stake by 828% in Q1 2026, buying an estimated $2.13M and bringing the position to 39,436 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4901.

UBS Group first reported a position in MNPR in Q4 2019 and has held it in 20 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • UBS Group held 39,436 shares of Monopar Therapeutics worth $2.16M as of Q1 2026.
  • UBS Group bought 35,186 Monopar Therapeutics shares in Q1 2026, an estimated $2.13M.
  • Monopar Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4901 holding.
  • UBS Group first reported a position in Monopar Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.